UPDATE: Cantor Fitzgerald Reiterates Hold on Hologic; Raises PT from $20 to $21
Cantor Fitzgerald reiterated a Hold rating on Hologic (NASDAQ: HOLX) and raised its price target from $20 to $21.
Cantor Fitzgerald commented, “Following the close of Hologic's acquisition of Gen-Probe last week, we are updating our model to reflect the new combined entity. Due to integration challenges and ongoing macro/currency headwinds that put a slight damper on 3Q results, we remain at a HOLD but raise our PT from $20 to $21 (13x FY:2013 EPS).”
Hologic closed at $19.65 on Monday.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.